What is Biodesix's gross profit margin?

What is the revenue and EPS growth rate for Biodesix year over year?

What were the key takeaways from Biodesix's earnings call?

What is Biodesix's latest dividend and current dividend yield?

What were the key takeaways from Biodesix’s earnings call?

What does Biodesix do and what are its main business segments?

What factors drove the changes in Biodesix's revenue and profit?

What guidance did Biodesix's management provide for the next earnings period?

- **Revenue Growth**: 41% YoY in Q4, driven by 46% lung diagnostics and 41% development services expansion.
- **Profitability Milestone**: First positive adjusted EBITDA ($530K) and 83% gross margin, supported by 97-rep sales force.
- **Strategic Expansion**: Primary care penetration (12% of tests) and partnerships with Thermo Fisher/Bio-Rad fuel pipeline growth.
- **2026 Outlook**: $106-112M revenue target (+23% YoY), with focus on sales productivity and reimbursement optimization.

**【CEO Opening Remarks】**
- Biodesix achieved 41% year-over-year revenue growth in Q4 2025, driven by lung diagnostics and development services.
- Gross margin improved to 83%, with adjusted EBITDA turning positive at $530,000 for the quarter.
- Expanded commercial strategy into primary care, accounting for 12% of Nodify test volumes (up 67% YoY), complementing pulmonology growth (26% YoY).
- Launched partnerships with Thermo Fisher and Bio-Rad to advance multi-omic diagnostic pipelines.

**【CFO Financial Commentary】**
- Total revenue: $28.8M (Q4) / $88.5M (FY25), +41% / +24% YoY.
- Lung Diagnostics: $25.1M (Q4) / $79.2M (FY25), +46% / +22% YoY, with 40% core organic growth.
- Development Services: $3.6M (Q4) / $9.3M (FY25), +12% / +41% YoY.
- Operating expenses: $25.8M (Q4) / $99.7M (FY25), +14% / +10% YoY, driven by sales force expansion to 97 reps.
- Pro forma cash: $33.7M (including $14.7M ATM proceeds post-Q4), supporting 2026 guidance of $106-112M revenue (+23% YoY).

**【Q&A Highlights】**
- **Revenue Seasonality**: Q1 typically sees ASP and volume step-downs due to deductible resets and weather disruptions.
- **Pipeline Progress**: MRD test combining proteomics and genomics, VeriStrat expansions into colorectal and prostate cancer, and AI-driven digital diagnostics in development.
- **Sales Force Strategy**: 2026 plans to add 6 reps/QTR, focusing on primary care and pulmonology penetration.
- **HEDIS Guidelines**: No updates on 2026 lung cancer screening guidelines, but ongoing advocacy for earlier detection.
- **Clinical Impact**: Primary care adoption shifts diagnosis to earlier stages, with real-world data showing improved outcomes.

Biodesix, Inc. (BDSX) Q4 2025 Earnings Call Transcript

- **Revenue Acceleration**: Q3 2025 revenue up 20% YoY to $21.8M, driven by 13% test volume growth and 16% lung diagnostics revenue increase.
- **Gross Margin Expansion**: 81% gross margin (vs. 77% YoY), reflecting cost efficiency and higher ASPs.
- **Primary Care Success**: 75% YoY growth in primary care test orders, with 11% of Nodify tests now from PCPs.
- **Updated Guidance**: Full-year 2025 revenue raised to $84-86M, targeting Q4 adjusted EBITDA positivity.

**【CEO Opening Remarks】**
- **Revenue Growth**: Q3 2025 revenue reached $21.8 million, up 20% YoY, driven by 13% test volume growth and 16% revenue growth in lung diagnostics.
- **Gross Margin Expansion**: Gross margin improved to 81% (up 400bps YoY) due to cost control and higher ASPs.
- **Primary Care Expansion**: 11% of Nodify tests now ordered by primary care providers (vs. 4% pre-pilot), with 75% YoY growth in Q3.
- **CLARIFY Study Progress**: Presented interim data showing real-world performance of Nodify CDT, aligning with clinical research sensitivity/specificity.
- **Sales Team Scaling**: 85 reps in Q3 (up from 65 in Q1), targeting 93-97 reps in Q4 and 6 reps/Q in 2026.

**【CFO Financial Commentary】**
- **Revenue Breakdown**: $19.8M in lung diagnostics (16% YoY), $1.9M in development services (97% YoY growth).
- **Profitability**: Net loss narrowed to $8.7M (-15% YoY), adjusted EBITDA loss of $4.6M (-18% YoY). 
- **Cash Position**: $16.6M in unrestricted cash, with $5.2M increase in AR due to higher collections timing.
- **Guidance Update**: Full-year 2025 revenue raised to $84-86M (vs. prior $80-83M), targeting Q4 adjusted EBITDA positivity.

**【Q&A Highlights】**
- **Primary Care Validation**: Primary care physicians report earlier cancer detection, reducing missed diagnoses. 
- **Sales Rep Productivity**: Targeting $1M+ per rep, with 50 territories fully staffed by end-2025.
- **Medicare Advantage Progress**: One major plan resumed paying claims, but back pay collection remains uncertain.
- **Capital Needs**: No immediate funding required; ATM used to offset AR timing, with Q4 collections strong.


Biodesix, Inc. (BDSX) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: 12% YoY to $20M, with 53% jump in Development Services
- **Gross Margin Expansion**: 80% (up 150bps YoY)
- **Primary Care Success**: 9% of tests now from primary care (vs. 4% pre-pilot)
- **Pipeline Momentum**: ALTITUDE study meets enrollment; VeriStrat shows utility in cancer treatment
- **EBITDA Target**: On track for Q4 breakeven with no cost-cutting needed
- **HEDIS Delay**: Impact on lung screening measures pushed out

**【CEO Summary Section】**
- **Revenue Growth**: Q2 2025 revenue of $20.0 million, up 12% YoY, driven by 9% test volume growth in lung diagnostics and 53% year-over-year growth in Development Services. 
- **Gross Margin Expansion**: Improved to 80% (up 150bps YoY) due to operational efficiency and cost control.
- **Sales Strategy Success**: 
  - 13 new sales reps added (21% YoY increase to 74 reps)
  - Primary care test orders increased to 9% of total (vs. 4% pre-pilot)
  - On-site blood draw in primary care settings boosted test completion rate by 30%
- **Pipeline Progress**: 
  - ALTITUDE study met enrollment target; interim data expected in H2
  - MRD test combo of proteomics and genomics shows promise in early detection
  - VeriStrat test demonstrated utility in immunotherapy selection and prostate cancer
 $17.9M (1
**【CFO Financial Commentary】**
- **Revenue Breakdown**: 
  - Lung diagnostics:5,100 tests)
  - Development Services: $2.1M (53% YoY growth)
- **Profitability Metrics**: 
  - Gross margin: 80% (vs. 78.4% Q2 2024)
  - Adjusted EBITDA loss: $7.2M (29% YoY increase)
  - Cash balance: $20.7M
- **Guidance**: 
  - Full-year revenue $80-85M
  - Targeting EBITDA breakeven in Q4
  - $12.5M under contract in Development Services (54% YoY growth)

**【Q&A Key Highlights】**
- **Primary Care Strategy**: 
  - 100%+ growth in primary care orders vs. 2024 pilot
  - 10 new primary care-focused reps in field
  - 40% higher retention for practices using digital ordering
- **EBITDA Bridge**: 
  - Driven by sales force expansion and revenue leverage
  - No major cost-cutting initiatives planned
- **HEDIS Impact**: 
  - HEDIS delayed implementation of lung cancer screening measures
  - Company remains focused on incidentally detected nodules
- **Capital Needs**: 
  - Confident in existing cash and plans to achieve cash flow breakeven

Biodesix (BDSX)-7 Aug 25-2025 Q2 Earnings call transcript

- **Revenue Growth Acceleration**: Q1 2025 revenue up 21% YoY, driven by 18% growth in lung diagnostics.
- **Profitability Progress**: Gross margin expanded to 79.4%, with adjusted EBITDA positivity targeted for Q4 2025.
- **Sales Force Restructuring**: Reduced reps to 65 (from 71) to implement territory-based model, aiming for 95 reps by year-end.
- **Primary Care Expansion**: 58% increase in digital ordering adoption, with 40% higher retention for digital users.
- **Pipeline Momentum**: MRD test for biopharma use, VeriStrat showing promise in prostate cancer and immunotherapy response prediction.
- **Development Services Strength**: 61% YoY growth in services revenue, with $10.9 million under contract.


**【CEO Summary Section】**
- **Revenue Growth**: Q1 2025 revenue increased 21% YoY to $18 million, driven by lung diagnostic testing revenue of $16.3 million (18% YoY growth). Test volumes rose 16% to 13,800 from 11,900 in Q1 2024.
- **Gross Margin Expansion**: Gross margin improved to 79.4% (from 78.6% in Q1 2024), with plans for continued margin strength in the upper 70s.
- **Sales Force Restructuring**: Reduced sales reps from 71 to 65 to implement a territory-based model, targeting 95 reps by Q4 2025. Average rep productivity remains above $1 million/year.
- **Primary Care Expansion**: Launched a commercial pilot in primary care, focusing on 15,000 high-volume PCPs who manage 80% of lung nodule patients. Digital ordering adoption increased 58% YoY, with 40% higher retention for digital users.
- **Pipeline Progress**: Advanced MRD test combining genomics and proteomics for biopharma use, with VeriStrat showing promise in prostate cancer and immunotherapy response prediction.

**【CFO Financial Commentary】**
- **Financial Highlights**: GAAP net loss of $11.1 million (18% YoY improvement), adjusted EBITDA loss of $6.2 million (11% YoY improvement). Cash balance of $17.6 million, with a $10 million loan draw post-quarter.
- **Guidance Update**: Revised 2025 revenue guidance to $80-85 million due to delayed sales rep hiring. Targeting adjusted EBITDA positivity in Q4 2025.
- **Development Services**: Q1 revenue of $1.7 million (61% YoY growth), with $10.9 million under contract (21% YoY increase).

**【Q&A Key Highlights】**
- **Sales Force Challenges**: Hiring delays caused a one-quarter revenue impact, with plans to accelerate hiring to 10 reps/Q2. Rep productivity and cost control remain strong.
- **Primary Care Strategy**: Focused on 15,000 high-volume PCPs with on-site phlebotomy access. Early pilot success suggests potential for stage-shifting lung cancer detection.
- **MRD Commercialization**: Biopharma partnerships for MRD test development, with commercial launch expected in late 2025. Long-term plans for direct-to-pulmonologist sales.
- **Capital Management**: $10 million loan draw provides flexibility, with no immediate capital needs beyond 2025.


Biodesix, Inc. (BDSX) Q1 2025 Earnings Call Transcript

- **Revenue Growth**: 45% YoY to $71.3M, driven by 43% Lung Testing and 70% DDS growth.
- **Margin Expansion**: Gross margin 78%, adjusted EBITDA loss down 32%.
- **2025 Outlook**: $92-95M revenue, H2 EBITDA breakeven, 95 sales teammates targeting primary care.
- **Clinical Momentum**: CLARIFY study enrolling 600+ patients, ALTITUDE data possible mid-2025.
- **Cash Position**: $26.2M cash, confident in self-funding 2025 growth.

**【CEO Summary Section】**
- **2024 Yearly Performance**: Total revenue reached $71.3 million, a 45% YoY increase, with Lung Diagnostic Testing growing 43% and Diagnostic Development Services (DDS) up 70%. Gross margin improved to 78%, and adjusted EBITDA loss decreased by 32%.
- **Lung Diagnostic Expansion**: Launched a pilot program to target primary care physicians (PCPs), demonstrating success in accessing 49% of lung nodule patients initially managed by PCPs. Plan to expand sales team to 95 teammates by Q4 2025, supporting 50 territories.
- **Clinical Research Progress**: Initiated the CLARIFY study (n=4,000 patients) to validate Nodify tests and compare with PET scans. Also advancing the ALTITUDE study, with potential mid-2025 data release.
- **2025 Outlook**: Project $92-95 million in revenue, mid-to-upper 70s gross margin, and adjusted EBITDA breakeven in H2, driven by Lung Testing and DDS growth.

**【CFO Financial Commentary】**
- **Q4 2024 Results**: Total revenue $20.4 million (+39% YoY), with Lung Testing at $17.2 million (+34%) and DDS at $3.2 million (+72%). Full-year gross margin 78.2%, up 500bps YoY. Net loss narrowed to $8.3 million (-10% YoY), with adjusted EBITDA loss of $3.9 million (-19% YoY).
- **Cost Management**: Operating expenses grew 17% YoY to $90.2 million, driven by sales & marketing (+25%) and leasehold improvements. Ended with $26.2 million cash, confident in funding 2025 without additional debt draws.

**【Q&A Key Takeaways】**
- **Sales Strategy**: Piloting PCP engagement via pulmonologist referrals, with 60% of new hires focused on primary care. Expect territory segmentation to optimize coverage.
- **Profitability Path**: EBITDA breakeven in H2 2025 via revenue growth and expense control. Gross margin stability due to volume leverage and operational efficiency.
- **Pipeline Update**: No new test launches in 2025, but advancing MRD collaboration with Memorial Sloan Kettering. CLARIFY study data expected in 2025.
- **Cash Flow**: Anticipate Q1 cash burn, followed by sequential improvement. Current cash sufficient for 2025, with Perceptive loan as buffer.


Actual	-6	-5	-5.2	-8.2	-8.2	-9.8	-10	-8	-6.8	-7	-4.8	-3.4	-2.8	-2	-2.8	-1.6	-1.4	-1.2	-1.6	-1.6	-1.16	-0.49
Forecast	-5.7333	-8.037	-3.5	-5.7333	-9.55	-9.839	-8.5	-9.3	-6.553	-5.551	-4.7331	-4.1247	-2.9333	-2.1811	-2.8427	-1.8412	-1.4627	-1.3443	-1.3957	-1.3776	-1.49	-0.8603
Surprise	-4.65%	+37.79%	-48.57%	-43.02%	+14.14%	+0.40%	-17.65%	+13.98%	-3.77%	-26.10%	-1.41%	+17.57%	+4.54%	+8.30%	+1.50%	+13.10%	+4.29%	+10.73%	-14.64%	-16.14%	+22.15%	+43.04%

BDSX

BDSX fundamentals

BDSX Q4 2025 Earnings

Earnings Call

You can ask Aime

BDSX

BDSX fundamentals

BDSX Q4 2025 Earnings

Earnings Call

BDSX Earnings Call Summary for Q4/20254:30 PM on Feb 26, 2026

BDSX Earnings Call Summary for Q3/20254:30 PM on Nov 3, 2025

BDSX Earnings Call Summary for Q2/20254:30 PM on Aug 7, 2025

BDSX Earnings Call Summary for Q1/20254:30 PM on May 13, 2025

BDSX Earnings Call Summary for Q4/20244:30 PM on Mar 3, 2025

You can ask Aime